A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
β Scribed by K.A. Papp; S. Tyring; M. Lahfa; J. Prinz; C.E.M. Griffiths; A.M. Nakanishi; R. Zitnik; P.C.M. Van De Kerkhof; the Etanercept Psoriasis Study Group
- Book ID
- 108668255
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 256 KB
- Volume
- 152
- Category
- Article
- ISSN
- 0007-0963
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GOβRAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score β₯4, and a back pain score of β₯4 were randomly assigned in a 1.8:1.8:1
## Abstract ## Objective Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, and small studies have suggested similar efficacy in PsA. We undertook this doubleβblind,